USP10通过稳定PDAC中的PLK1促进进展,并通过稳定PDAC中的PLK1减弱凝胺化疗敏感性
Xuezhi Du1,2,3, Runze Yu2, Caigu Yan1
1Department of Hepatopancreatobiliary Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
Cell death & disease
|June 14, 2025
概括
通过稳定PLK1.1,USP10上调促进胰腺癌的进展和耐吉他的抗性. 用gemcitabine抑制USP10为胰腺管道腺癌提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种高度恶性癌症,结果不佳,通常与化疗耐药性有关.
- 乌比基特异性蛋白酶 (USP) 调节蛋白质稳定性,并与瘤进展有关,使它们成为潜在的治疗点.
研究的目的:
- 研究USP10在胰腺管腺癌 (PDAC) 进展中的作用及其对凝胺 (GEM) 化疗反应的影响.
主要方法:
- 在PDAC组织中对USP10的上调分析.
- 在体外和体内测试以评估USP10在PDAC进展中的作用.
- 同免疫沉 (CO-IP),免疫沉质谱和GST拉下测试用于识别USP10相互作用蛋白.
- 脱化试验以确定USP10对PLK1.1的影响.
- 用USP10抑制和GEM进行组合治疗的研究.
主要成果:
- USP10表达在PDAC中显著上调,与预后不佳相关.
- USP10在体外和体内都促进了PDAC的进展.
- USP10直接与PLK1相互作用并使其脱,增加了其稳定性.
- 通过PLK1,USP10通过PLK1促进PDAC细胞的自,有助于凝胺耐药性.
- 联合抑制USP10和GEM协同抑制了PDAC的进展.
结论:
- USP10通过稳定PLK1在PDAC中起到瘤促进作用,从而增强瘤进展并减弱凝胺敏感性.
- 针对USP10与gemcitabine结合,为PDAC提供了一个有前途的治疗策略.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K